# ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

> **NCT00407407** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 6 (actual)

## Conditions studied

- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Ovarian Neoplasms

## Interventions

- **DRUG:** ABI-007
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00407407
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11-01
- **Primary completion:** 2008-02-01
- **Final completion:** 2008-02-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** MTD not determined
- **Last updated:** 2019-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407407, "ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00407407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*